Search results
2 new COVID variants called 'FLiRT' are spreading in the U.S. What are the symptoms?
TODAY via Yahoo News· 1 day agoThe new "FLiRT" COVID-19 variants, including KP.2, are spreading in the United States. Will there be...
...-Phase Retina Pipeline including Advancements with High Drug-Antibody-Ratio Therapeutics Built on...
Casper Star-Tribune· 3 days agoKodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases ...
CDC says bird flu viruses "pose pandemic potential," cites major knowledge gaps
WINK TV Southwest Florida· 14 hours agoBird flu continues to appear to pose a “low risk to the general public” for now, the Centers for...
Regeneron Pharmaceuticals Inc (REGN) Q1 2024 Earnings Call Transcript Highlights: Key Financial ...
GuruFocus.com via Yahoo Finance· 2 days agoRevenue: Grew 7% year-over-year to $3.1 billion, excluding COVID antibodies contributions. Net Income: First quarter diluted net income per share was $9.55. Free Cash Flow: Generated $1.< ...
... III Randomized, Double-Masked Vehicle Controlled VELOS-4 Trial Evaluating Tanfanercept for...
WFRV 5 Green Bay· 2 days agoHanAll has initiated a Phase III VELOS-4 study to evaluate the efficacy and safety of tanfanercept in dry eye based on the findings from the previous Phase III VELOS-3 study ...
OraSure Technologies (NASDAQ:OSUR) Upgraded to Buy by StockNews.com
ETF DAILY NEWS· 3 days agoStockNews.com upgraded shares of OraSure Technologies (NASDAQ:OSUR – Free Report) from a hold rating to a buy rating in a report issued on Wednesday. Separately, Evercore ISI cut their price ...
FDA Issues Final Rule on Laboratory-Developed Tests | JD Supra
JD Supra· 3 days agoOn April 29, 2023, the FDA announced a final rule on regulation of laboratory developed tests (LDTs). The rule explicitly categorizes in vitro...
Realising the potential of correlates of protection for vaccine development, licensure and use:...
Nature· 6 days agoVaccine development, particularly late-stage development is costly, time-consuming and is associated with high risk of candidate failure, with as few as 10% of vaccine candidates achieving licensure ...
Ardelyx (ARDX) Reports Q1 Loss, Tops Revenue Estimates
Zacks· 3 days agoFree Report) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.13. This quarterly report represents an earnings surprise of 15.38%. A quarter ...
HanAll Biopharma Reports Q1 2024 Financial Results and Provides Business Update
FOX21 Colorado Springs· 5 days agoDelivered solid performance to start 2024, with record-breaking first quarter revenue of 34.1 billion KRW. Phase 3 VELOS-4 study of tanfanercept in dry eye disease expected ...